Alterity Therapeutics Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ATHE | GANX | LONA | VYGR | QNCX | ALEC | |
|---|---|---|---|---|---|---|
| Market cap | 53.35M | 68.52M | 58.08M | 139.87M | 32.27M | 232.25M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.1 | -2.3 | — | -1.8 | -6.8 | -2.8 |
| Price/book | 1.8 | 6.0 | 1.7 | 0.9 | -0.9 | -23.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −38.05% | −13.68% | +53.74% | −49.90% | −91.91% | −30.43% |
| Today | −6.98% | −4.27% | +7.22% | −7.35% | +8.07% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ATHE news ›Total equity of Alterity Therapeutics Ltd. TEMP – CHIXAU:ATHN
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral…
Cash flow from financing activities of Alterity Therapeutics Ltd. TEMP – CHIXAU:ATHN
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral…
After tax other income/expense of Alterity Therapeutics Ltd. TEMP – CHIXAU:ATHN
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral…
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the…
Alterity Therapeutics CEO to present on October 12
MINERAL EUROPA: A GAME CHANGER FOR SHIPPING Alterity says it is preparing to initiate a Phase 3 pivotal trial in MSA, which it describes as a rare and rapidly progressive disease. Alterity Therapeutics Limited (ATHE) announced that Chief…
Alterity Therapeutics CEO Dr. David Stamler to Speak at Canaccord Genuity Drug and Device Conference on October 12, 2026
Kalkine Media Alterity Therapeutics (ASX:ATH) ATH (ASX:ATH) , a biotechnology firm specializing in treatments for neurodegenerative disorders, announced that its CEO, David Stamler, M.D., will present at the Canaccord Genuity Drug and…
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Flyte Aviation Launches Under NYSE American Ticker “VJET” The adjusted functional result exceeded the clinically meaningful threshold, but the trial missed its primary imaging endpoint. How this balance works Rhea-AI gives every point it…
Alterity Therapeutics sets November 20 annual meeting
Director nominations must be received in writing at Alterity’s registered office by October 2, 2026, before its November 20 AGM. Alterity Therapeutics Limited (ATHE) said its next Annual General Meeting will be held at 11.00am AEDT on…
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 For the month of September 2026 Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net4
-
tradingview.com3
-
kalkine.com.au1
-
kalkinemedia.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.